Skip to content

Study · In vitro (cells) · 2010

5 results

Humanin is expressed in human vascular walls and has a cytoprotective effect against oxidized LDL-induced oxidative stress.

Bachar AR, Scheffer L, Schroeder AS, Nakamura HK, Cobb LJ, Oh YK, Lerman LO, Pagano RE, Cohen P, Lerman A

Cardiovascular research18 Jun 2010Cited by 152 (Europe PMC)

PMID20562421 (opens in a new tab)PMCIDPMC2952532 (opens in a new tab)DOI10.1093/cvr/cvq191 (opens in a new tab)PepBankPUB-20562421
Source linkPubMedAsk about this study
Jump to 5 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study5

3 results from studies that gave the peptide. No result from this study comes from people.

  1. 01LabIn vitro (cells)Mechanism

    In human aortic endothelial cells, pre-treatment with 0.1 µM humanin reduced oxidized LDL-induced formation of reactive oxygen species by 50%.

    In plain wordsIn cells, humanin cut the oxidative stress that oxidized LDL caused in blood vessel cells by about half.

    Peptide
    Humanin
    Outcome
    DecreaseOx-LDL-induced reactive oxygen species
    Study

    humann: not reported in source

    Human aortic endothelial cells (HAECs)
    Comparator
    Ox-LDL without humanin
    Outcome group
    Inflammation markers · Cardiovascular
    Studied dose
    0.1 µMAs given in this study (human).

    Measurements

    ROS reduction
    50%
    0.1 µM HN

    Source sentences

    Summary
    Pre-treatment with 0.1 µM HN reduced oxidized LDL (Ox-LDL)-induced (i) formation of reactive oxygen species by 50%, (ii) apoptosis by ∼50% as determined by TUNEL staining, and (iii) formation of ceramide, a lipid second messenger involved in the apoptosis signalling cascade, by ∼20%.
    1 context sentence
    Summary · context
    Cytoprotective effects of HN against oxidative stress were tested in vitro in HAECs.
  2. 02LabIn vitro (cells)Efficacy outcome

    In human aortic endothelial cells, pre-treatment with 0.1 µM humanin reduced oxidized LDL-induced apoptosis by about 50% by TUNEL staining.

    In plain wordsIn cells, humanin cut cell death caused by oxidized LDL in blood vessel cells by about half.

    Peptide
    Humanin
    Outcome
    DecreaseOx-LDL-induced apoptosis (TUNEL)
    Study

    humann: not reported in source

    Human aortic endothelial cells (HAECs)
    Comparator
    Ox-LDL without humanin
    Outcome group
    Myocardial injury · Cardiovascular
    Studied dose
    0.1 µMAs given in this study (human).

    Source sentences

    Summary
    Pre-treatment with 0.1 µM HN reduced oxidized LDL (Ox-LDL)-induced (i) formation of reactive oxygen species by 50%, (ii) apoptosis by ∼50% as determined by TUNEL staining, and (iii) formation of ceramide, a lipid second messenger involved in the apoptosis signalling cascade, by ∼20%.
    1 context sentence
    Summary · context
    Cytoprotective effects of HN against oxidative stress were tested in vitro in HAECs.
  3. 03LabIn vitro (cells)Mechanism

    In human aortic endothelial cells, pre-treatment with 0.1 µM humanin reduced oxidized LDL-induced ceramide formation by about 20%.

    In plain wordsIn cells, humanin lowered ceramide, a cell-death signal, by about 20% in blood vessel cells exposed to oxidized LDL.

    Peptide
    Humanin
    Outcome
    DecreaseOx-LDL-induced ceramide formation
    Study

    humann: not reported in source

    Human aortic endothelial cells (HAECs)
    Comparator
    Ox-LDL without humanin
    Outcome group
    Receptor activity and mechanism · Cardiovascular
    Studied dose
    0.1 µMAs given in this study (human).

    Source sentences

    Summary
    Pre-treatment with 0.1 µM HN reduced oxidized LDL (Ox-LDL)-induced (i) formation of reactive oxygen species by 50%, (ii) apoptosis by ∼50% as determined by TUNEL staining, and (iii) formation of ceramide, a lipid second messenger involved in the apoptosis signalling cascade, by ∼20%.
    1 context sentence
    Summary · context
    Cytoprotective effects of HN against oxidative stress were tested in vitro in HAECs.

Natural levels measured2

These results measure the body's own peptide. Nobody was given the peptide. They are not evidence about taking it. They are left out of key results, evidence counts and charts.

  1. 04LabEndogenous levelEx vivo tissueOther

    Humanin was detected by immunostaining in the endothelial cell layer of human internal mammary arteries, atherosclerotic coronary arteries and saphenous vein sections.

    In plain wordsThe body's own humanin was found in the inner cell layer of human blood vessels.

    Peptide
    Humanin
    Outcome
    Not applicableHumanin expression in human vessels
    Study

    humann: not reported in source

    Human internal mammary arteries, atherosclerotic coronary arteries and saphenous vein sections
    Outcome group
    Endogenous peptide levels · Cardiovascular

    Source sentences

    Summary
    HN expression in the vascular wall was detected by immunostaining in the endothelial cell layer of human internal mammary arteries (n = 5), atherosclerotic coronary arteries (n = 17), and sections of the greater saphenous vein (n = 3).

    This result measures the body's own Humanin. Nobody was given the peptide. It is not evidence about taking it.

  2. 05LabEndogenous levelIn vitro (cells)Other

    Humanin mRNA was expressed in human aortic endothelial cells.

    In plain wordsIn cells, human aortic endothelial cells made the body's own humanin mRNA.

    Peptide
    Humanin
    Outcome
    Not applicableHumanin mRNA expression in aortic endothelial cells
    Study

    humann: not reported in source

    Human aortic endothelial cells (HAECs)
    Outcome group
    Endogenous peptide levels · Cardiovascular

    Source sentences

    Summary
    HN mRNA was expressed in the human aortic endothelial cells (HAECs).

    This result measures the body's own Humanin. Nobody was given the peptide. It is not evidence about taking it.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    13 Oct 2026, 21:44 UTC

    Study results updated

  2. Version 1

    13 Oct 2026, 16:31 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.